The Midlands does not have an innovation problem. It has an execution problem.

For more than a decade, millions of pounds have been channelled into government-funded accelerator programmes, incubation schemes, innovation vouchers, university enterprise initiatives, and publicly supported ecosystem projects across both the East and West Midlands. Yet despite all of this activity, the Midlands still struggles to consistently produce globally scaled MedTech and Life Sciences companies.

The region has world-class ingredients. The East Midlands alone has strong universities, NHS connectivity, advanced manufacturing capability, transport infrastructure, and significantly lower operating costs than those of London, Oxford, and Cambridge. The region still lacks a commercially aggressive, internationally focused execution platform dedicated to attracting, commercialising, and scaling healthcare innovation. Instead, too much of the ecosystem has become dependent on fragmented grant structures, academic-led programmes, and publicly funded initiatives that often prioritise engagement metrics over measurable commercial outcomes.

The West Midlands has arguably been more coordinated and visible in building external investment narratives and strategic positioning. The East Midlands, meanwhile, continues to suffer from fragmentation, overlapping support programmes, and a lack of commercial leadership capable of driving international growth strategies.

Academia absolutely has a role to play. Research institutions are critical for discovery, translational science, and technical capability. But universities should not dominate the scaling agenda. Early-stage companies do not scale through academic committees alone. They scale through commercial execution, regulatory strategy, clinical deployment, manufacturing partnerships, investor access and operational leadership.

This is where many regional programmes fail.

The UK has created an environment in which support for innovation often becomes administrative rather than commercial. Founders are pushed through workshops, innovation frameworks, and short-term accelerators, yet remain disconnected from real procurement pathways, international expansion support, manufacturing scale-up infrastructure, and serious capital formation strategies.

Even established organisations that once played an important ecosystem role, such as Medilink Midlands, now risk becoming legacy membership structures operating in ecosystems that require far more aggressive commercial execution models. Networking events and stakeholder engagement alone will not build globally competitive healthcare businesses.

Meanwhile, Europe is moving faster.

Across parts of continental Europe, innovation agencies increasingly operate like strategic development corporations — integrating inward investment, manufacturing partnerships, regulatory acceleration, export support, and commercialization infrastructure into coordinated growth systems.

The Midlands should be asking itself a difficult question:

How much public money has been spent supporting “innovation activity” versus actually building scalable commercial healthcare enterprises?

This is precisely why organisations like MedTech Makers Lab were created.

MedTech Makers Lab does not operate as a traditional innovation consultancy or passive accelerator. It operates as a private-sector development agency built around execution.

That means:

• building international innovation corridors

• supporting regulatory and NHS market access pathways

• structuring commercialization strategies

• aligning companies with investors and strategic capital

• supporting manufacturing and scale-up partnerships

• developing cross-border expansion programmes

• embedding companies into operational healthcare ecosystems

• helping founders move from research to revenue and ultimately toward enterprise value growth

• 
  

This is not theory-driven ecosystem management. It is execution-led economic development. Local governments across the Midlands should pay very close attention to this shift.

The next generation of regional growth will not come from more fragmented accelerator programmes or another layer of publicly funded ecosystem management. It will come from commercially disciplined organisations capable of acting at private-sector speed while integrating government, healthcare systems, investors, manufacturers, and international markets into one coordinated growth platform.

The Midlands does not need another talking shop. It needs a real MedTech and Life Sciences development engine capable of attracting global companies, accelerating NHS adoption, supporting manufacturing growth, and positioning the region as a gateway into UK and European healthcare markets.

The regions that learn how to execute innovation — not just discuss it — will dominate the next decade of healthcare and deep technology growth.